RESEARCH PAPER

Recent Advances in Biomaterial-Driven 3D Printing for Bone Tissue Engineering

Mrunali Patel[1], Jignesh Mevada[2], Arpan Doshi[3], Bharat Doshi[4]

[1]Department of Biotechnology, U.V. Patel College of Engineering, Ganpat University, Mehsana, Gujarat, India

[2]Department of Mechatronics Engineering, U.V. Patel College of Engineering, Ganpat University, Mehsana, Gujarat, India

[3]Orthopedic Surgeon, The Royal Orthopaedic Hospital

[4]Department of Mechanical Engineering, U.V. Patel College of Engineering, Ganpat University, Mehsana, Gujarat, India

Corresponding Author: Dr. Jignesh Mevada, Department of Mechatronics Engineering, U.V. Patel College of Engineering, Ganpat University, Mehsana, Gujarat, India

Email: Jignesh.mevada@ganpatuniversity.ac.in

ABSTRACT

The integration of biotechnology, nanotechnology, and 3D bioprinting has significantly advanced bone tissue engineering by providing novel approaches for bone and cartilage regeneration. Biomimetic scaffolds composed of self-assembling peptides, nanomaterials, and bioactive compounds facilitate the development of biodegradable, bioactive, and mechanically stable structures for repairing bone defects. Clinical translation remains constrained due to challenges such as weak mechanical performance, uncontrolled degradation rates, immune system responses, and suboptimal drug delivery efficiency. This paper reviews emerging strategies aimed at enhancing scaffold performance, including the incorporation of carbon nanotubes and graphene oxide for structural reinforcement, the design of multi-responsive hydrogels, enzyme-responsive degradation mechanisms, and nanocarrier-mediated drug delivery systems. In addition, computational modeling and AI-assisted 3D bioprinting are highlighted as promising technologies for the assembly of personalized and scalable scaffolds. By overcoming current limitations, these next-generation scaffolds have the potential to improve osteointegration, maintain long-term bioactivity, and enhance clinical outcomes. This review summarizes recent innovations in biomaterials and discusses future directions for developing effective and personalized bone tissue engineering solutions.

Key words: Bone Tissue Engineering, 3D Bioprinting, Biomimetic Scaffolds, Nanomaterial Reinforcement, Osteointegration.

How to cite this article: Patel M, Mevada J, Doshi A, Doshi B. Recent Advances in Biomaterial-Driven 3D Printing for Bone Tissue Engineering. Int J Drug Deliv Technol. 2026;16(53s): 376-386. DOI: 10.25258/ijddt.16.53s.86

Source of support: Nil.

Conflict of interest: None

.

Introduction

The paper explores the integration of bioprinting, nanotechnology, and smart biomaterials in bone tissue engineering and regenerative medicine. It highlights recent advancements in biomimetic scaffolds, including self-assembling peptides, nanomaterials, and bioactive molecules. These innovations have significantly enhanced the mechanical strength, bioactivity, and biodegradability of bone graft substitutes. It further examines how technologies such as computational modeling and 3D bioprinting are revolutionizing scaffold fabrication. These tools enable personalized and scalable strategies to effectively address bone defect repair.

Another key objective of the paper is to analyze future trends and translational challenges in the field. While innovative biomaterials and scaffold technologies have shown promising preclinical results, their clinical applications remain limited due to issues such as immune responses, mechanical instability, inefficient drug delivery, and regulatory hurdles. The paper delves into strategies to enhance scaffold performance, including carbon nanotube reinforcement, multi-responsive hydrogels, and enzyme-sensitive degradation systems. Additionally, the paper addresses the economic and regulatory barriers that limit the widespread implementation of bioprinted scaffolds. It also proposes innovative strategies to support clinical translation and market adoption.



Fig. 1. The development of 3D printing technology in biomedical applications is divided into five stages according to the properties of the building blocks [1]. Copyright 2020, IOP Publishing.

Bone defects caused by trauma, infections, congenital disorders, tumors, or osteoporosis represent a major clinical and socioeconomic issue, often requiring surgical procedures to restore normal function and structural integrity [1–2]. Each year, more than 2 million bone graft surgeries are performed worldwide. Although traditional grafting techniques such as

autografts, allografts, and xenografts are widely used, they are associated with several limitations, including donor-site morbidity, immune rejection, and the risk of infection [3–6]. Autograft procedures, in particular, can result in donor-site complications in up to 20% of patients. Alternatively, tissue engineering and regenerative medicine offer advanced solutions by combining biomaterials, cells, and bioactive



molecules to design engineered scaffolds that promote bone healing and regeneration [7–8].

Fig. 2. 3D bioprinting integrates conventional 3D printing, imaging, and cell-laden gels to fabricate functional tissues for regenerative medicine, pharmaceutical preclinical drug screening, and animal-free meat production [4].

Bone Biology and Regeneration: Overview

Bone is a dynamic, highly vascularized connective tissue that plays critical roles in structural support, mineral homeostasis, and hematopoiesis. Unlike most tissues, bone possesses an intrinsic ability for self-repair, facilitated by a coordinated interplay of cellular, molecular, and biomechanical processes. Bone remodeling occurs continuously throughout life and is essential for maintaining skeletal integrity. Bone consists of a composite matrix composed of organic and inorganic components. The organic matrix, primarily composed of type I collagen, provides tensile strength, while the inorganic mineral phase, mainly hydroxyapatite [$Ca_{10}(PO_4)_6(OH)_2$], provides compressive strength. Bone tissue is organized into two structural types: cortical bone, which forms the dense outer surface, and trabecular bone, which forms the porous internal network optimized for metabolic activity. This architecture supports both mechanical demands and metabolic functions such as calcium and phosphate storage.



Fig. 3. Bone Tissue Engineering and Bone Scaffolding

Cellular Players in Bone Biology

Bone homeostasis is controlled by four primary cell types:

- Osteoblasts, derived from mesenchymal stem cells (MSCs), synthesize new bone matrix and regulate mineralization.
- Osteoclasts, derived from the hematopoietic lineage, are multinucleated cells responsible for bone resorption.
- Osteocytes, former osteoblasts embedded within the matrix, function as mechanosensors and orchestrators of bone remodeling through signaling molecules such as sclerostin.
- Bone-lining cells, which regulate surface remodeling processes.

Communication among these cells is regulated through molecular pathways, including RANK/RANKL/OPG, Wnt/β-catenin, and TGF-β/BMP signaling.

Bone Remodeling and Repair Mechanisms

Bone remodeling is a lifelong process involving repeated cycles of resorption and formation. During remodeling, osteoclasts first degrade old or damaged bone, followed by osteoblast-mediated formation of new matrix. Mechanical loading, hormonal signals, and local biochemical cues regulate this process, enabling adaptation to functional demands.

In response to injury, bone undergoes a well-orchestrated regeneration process typically described in four phases:

1. Inflammation – Recruitment of immune cells and release of cytokines initiate the repair process.
2. Soft callus formation – Mesenchymal stem cells (MSCs) differentiate into chondrocytes, producing a fibrocartilaginous callus.
3. Hard callus formation – The callus is replaced by woven bone through endochondral ossification.
4. Remodeling – Woven bone transitions into mature lamellar bone, restoring mechanical strength and architecture.

Unlike many tissues, bone regeneration often restores the original structure and function without scar formation.

Clinical Considerations and Limitations: Although bone possesses an inherent capacity for healing, large defects, osteoporosis, trauma, tumor resection, infection, and impaired vascularity can compromise regeneration. In such cases, interventions such as bone grafts, tissue-engineered scaffolds, and growth factor therapies are used to enhance repair. Therefore, understanding bone biology is fundamental to

advancing strategies in bone tissue engineering and regenerative medicine.

Types of Biomaterials for Tissue Engineering

1. Natural Polymers

Natural polymers are widely used in bone tissue engineering due to their biocompatibility, biodegradability, and ability to mimic the extracellular matrix (ECM) [9]. These materials provide a suitable environment for cell attachment, proliferation, and differentiation, thereby promoting bone regeneration. Common examples include:

- **Collagen** – The primary structural protein in the bone ECM, collagen enhances cell adhesion and osteogenic differentiation [10,15]. Collagen-based scaffolds can be further modified to improve their mechanical properties and control their degradation rate.
- **Chitosan** – A polysaccharide with inherent antimicrobial properties, chitosan promotes osteoconductivity and facilitates controlled drug delivery [15,31]. Chitosan can be processed into various forms, including hydrogels, films, and fibers, offering versatility in scaffold fabrication.
- **Silk Fibroin** – A biocompatible protein that provides excellent mechanical strength and flexibility, making it well suited for scaffold fabrication [15,30–31]. Silk fibroin scaffolds can be engineered with controlled porosity and mechanical properties to meet specific application requirements.

2. Synthetic Polymers

Synthetic polymers are preferred for their controlled degradation, tunable mechanical properties, and ease of processing. They are often used in combination with bioactive materials to improve bone regeneration. Examples include:

- **Poly (lactic-co-glycolic acid) (PLGA)** – A widely used biodegradable polymer in drug delivery systems and scaffolds, PLGA offers a controllable degradation rate. This characteristic is crucial for matching the pace of scaffold degradation with the rate of new bone formation.
- **Polycaprolactone (PCL)** – A slow-degrading polymer with excellent mechanical properties, PCL is commonly employed in load-bearing applications. To enhance its bioactivity, PCL is often combined with other polymers or bioactive components.
- **Poly (ethylene glycol) diacrylate (PEGDA)** – A hydrogel-forming polymer, PEGDA enhances cell encapsulation and facilitates nutrient transport within scaffolds [31]. PEGDA hydrogels can be crosslinked to form porous structures that support cell growth and tissue development.

3. Bioactive Ceramics and Composites

Bioactive ceramics and composites are used to enhance osteointegration and stimulate bone mineralization. These materials closely resemble the mineral phase of natural bone and provide superior osteoconductivity. Key examples include:

- **Hydroxyapatite (HA)** – A calcium phosphate-based material, HA promotes bone cell attachment and mineralization [16]. HA exhibits high biocompatibility and can be synthesized with controlled particle size and morphology to tailor its properties.
- **Beta-Tricalcium Phosphate (β-TCP)** – A biodegradable ceramic with high osteoconductivity and resorption properties [12].
- **Bioglass** – A bioactive material that stimulates bone regeneration by releasing ions that promote cell signaling [4]. Bioglass can form a strong bond with bone tissue and enhance angiogenesis, thereby contributing to improved bone healing.

Role and design of Bio Materials Scaffolds

The development of biomaterial scaffolds is pivotal in clinical bone tissue engineering, as they offer essential structural support and a biologically favorable environment for cell adhesion, proliferation, and differentiation which ultimately accelerating healing and enhancing functional recovery in bone defect repair. In regenerative medicine, scaffolds mimic the natural extracellular matrix (ECM), providing a framework for cell adhesion, migration, and proliferation while facilitating tissue regeneration [9-10]. Current research in scaffold design focuses on enhancing mechanical strength, biodegradability, and bioactivity to ensure better integration with native tissues. One of the major challenges in bone repair is the lack of vascularization, which limits nutrient and oxygen diffusion in large defects. To address this, biomaterial scaffolds are being designed with angiogenic peptides, functionalized nanomaterials, and smart hydrogel systems that promote blood vessel formation and sustain cell viability. Moreover, scaffolds play a crucial role in the targeted delivery of drugs and growth factors, facilitating the controlled and localized release of osteogenic and angiogenic agents such as bone morphogenetic protein-2 (BMP-2), vascular endothelial growth factor (VEGF) and transforming growth factor-beta 3 (TGF-β3)

[11-14]. This approach not only promotes effective bone regeneration but also minimizes systemic side effects [15].

Biomaterial scaffolds must also be tailored to load-bearing applications, particularly in weight-bearing bones like the femur and tibia [17]. Traditional ceramic-based scaffolds such as hydroxyapatite and β-tricalcium phosphate, while highly osteoconductive due to their chemical similarity to bone mineral, often suffer from inherent brittleness (fracture toughness MPa·m1/2 compared to 2-12 MPa·m^0.5 for natural bone) and catastrophic mechanical failure under physiological stress, with failure rates exceeding 40% in load-bearing applications - with reference [18]. To overcome this, hybrid nanocomposites incorporating graphene oxide, hydroxyapatite, and bioactive glass are being developed to reinforce scaffold strength while maintaining bioactivity [15-19]. Enzyme-sensitive and pH-responsive degradation mechanisms allow scaffolds to degrade in concert with new bone formation, preventing early failure or prolonged persistence [20]. Computational modeling and AI-driven design strategies are being integrated to optimize scaffold architecture, degradation profiles, and biomechanical performance. Nevertheless, high production costs, regulatory approvals, and immune reactions remain significant barriers to clinical translation [21]. The future of biomaterial scaffolds in clinical applications lies in developing cost-effective, patient-specific, and 3D-bioprinted solutions that ensure optimal osteointegration, sustained bioactivity, and long-term success in regenerative medicine [22-23].

Limitations of current bone grafting techniques

Traditional bone repair methods, such as autografts, allografts, and synthetic implants, have significant drawbacks that limit their effectiveness in clinical applications. Autografts, which involve harvesting bone from the patient's own body, often lead to donor site morbidity, infection risks, and limited bone availability [24-25]. Allografts, derived from cadaveric donors, face challenges related to immune rejection, disease transmission, and inconsistent osteoinductive properties [26]. Although synthetic implants provide a convenient and accessible option, they often fall short due to limited biocompatibility, insufficient bioactivity, and mechanical properties that fail to align with those of native bone tissue [17]. These limitations have driven the demand for biomimetic scaffolds that integrate bioactive materials to promote better bone regeneration [6].

- **Autografts:**
- Advantages: High biocompatibility, no risk of immune rejection.
- Disadvantages: Donor site morbidity (pain, infection, fracture), limited tissue availability, additional surgical procedure.
- **Allografts:**
- Advantages: Readily available, can fill large defects.
- Disadvantages: Risk of disease transmission, potential for immune rejection, variable quality, ethical concerns.
- **Synthetic Implants:**
- Advantages: Abundant availability, customizable, can be designed with specific properties.
- Disadvantages: Lack of bioactivity, potential for fibrous tissue encapsulation, mismatch in mechanical properties, risk of infection.

Complication rates for traditional bone repair methods vary by graft type, surgical site, and patient condition—but all three major techniques (autografts, allografts, and synthetic bone substitutes) show notable complication rates that influence clinical decision-making.

Complication Rates of Traditional Bone Grafting Techniques

Traditional bone grafting methods, including autografts, allografts, and synthetic grafts, are widely used but associated with notable complication rates. Autografts, although considered the gold standard, show 10–30% complications, mainly due to donor site pain, nerve injury, infection, and limited availability. Allografts present a 15–35% complication rate, including immune reactions, graft failure, infection risk, and possible disease transmission. Synthetic grafts demonstrate 5–20% complications, often related to poor mechanical strength, slow resorption, inflammation, and limited biological activity. Overall, these limitations highlight challenges such as morbidity, immune response, and inadequate osteointegration, driving the development of advanced tissue engineering and biomaterial-based regenerative strategies.

Techniques for Bio Material 3D printing

Bioprinting is an innovative technology that integrates 3D printing with cellular biology to engineer customized tissue constructs and organ models. Initially developed for non-biological applications, 3D printing has evolved through advancements in bioink development—specialized materials incorporating living cells—to enable the precise fabrication of functional biological structures, bridging the gap between traditional manufacturing and regenerative medicine. Bioprinting technologies are categorized into three major modalities based on their deposition mechanisms, which can be used individually or in combination for tissue fabrication:

1. Extrusion based bioprinting

2. Droplet based bioprinting



[31,32, 33]	aggregates	alginate,	hydrogels
Cell Viability [31,32,33]	Moderate (40–80%), can reach up to ~97% with	High (>85%) due to minimal shear stress during printing.	Excellent (>95% initially); may decline over time due to photothermal effects.
Structural Integrity [31,32, 33]	High; continuous filament deposition ensures	Moderate; dependent on droplet coalescence and crosslinking efficiency.	Excellent; produces precise, porous microarchitectures with strong mechanical properties.
Limitations	Nozzle clogging; shear stress on cells; lower resolution.	Limited to low-viscosity inks; droplet placement precision challenges.	Expensive
Typical Applications [17, 31, 35]	Bone	Skin printing, drug screening models, and vascular tissue.	Microvascular networks, corneal scaffolds, and nerve regeneration constructs.

3. Laser based bioprinting

Fig. 4: The figure illustrates key 3D bioprinting methods: laser-assisted techniques (LIFT and LIBP), photopolymerization methods (TPP and DLP), and extrusion-based methods [54]

Feature *(References)*	Extrusion-Based Bioprinting	Droplet-Based Bioprinting	Laser-Based Bioprinting
Printing Mechanism [1,31,32]	Continuous deposition of bioink through	Discrete	High-pressure
Deposition System [21,31,32]	Pneumatic, piston-driven, or screw-based	Inkjet, electrohydrodynamic jet, acoustic droplet ejection, or microvalve systems.	Laser-Induced Forward Transfer
Resolution [31,32,33]	Moderate (~100 μm); suitable macrostructural fidelity.	Lower	High resolution (<50 μm); ideal for microscale structures and precision applications.
Printing Speed [31,32,33]	High throughput; suitable for large constructs and rapid production.	High, especially with multi-nozzle configurations.	Moderate; speed depends on laser scanning parameters and material response time.
Bioink Compatibility	Broad compatibility with high-viscosity hydrogels	Limited	Versatile;

Table 1: Comparison of Major 3D Bioprinting Techniques for Scaffold Fabrication

Innovations in Bone Tissue and scaffolding Engineering

Why New Bone Regeneration Strategies Are Needed?

Bone defects resulting from trauma, tumor resection, infection, or congenital abnormalities continue to present significant clinical challenges. While traditional grafting methods—autografts, allografts, and synthetic bone substitutes—have served as the foundation of reconstructive orthopedics for decades, each of these approaches has limitations that restrict their reliability and long-term success. These drawbacks, combined with an increasing burden of musculoskeletal disorders worldwide, create a

strong need for next-generation bone regeneration strategies.

Autografts remain the clinical gold standard due to their inherent osteogenic, osteoinductive, and osteoconductive properties. However, their effectiveness is limited by donor site morbidity, inadequate graft volume, and prolonged postoperative pain. Reported complication rates range from 10–30%, with donor site pain persisting in up to 20% of patients. These issues make autografts unsuitable for large bone defects or complex reconstructions. Allografts, although more widely available, lack living cells and therefore exhibit reduced osteogenic potential. They are associated with high rates of nonunion (10–25%), graft resorption, and immune-mediated complications. Additionally, despite strict screening procedures, allografts carry a residual risk—although extremely low—of disease transmission. Synthetic bone substitutes address donor-site limitations and avoid immunogenicity, yet their biological performance remains inferior. Many bioceramics and polymers are only osteoconductive and fail to support adequate vascularization or remodeling, leading to inconsistent integration and mechanical failure in up to 10–20% of cases.

The limitations of these traditional methods highlight a deeper clinical need: large, segmental bone defects require materials capable of promoting rapid vascularization, supporting mechanical loading, and facilitating complete biological integration. As the global incidence of osteoporosis, diabetes, and complex fractures increases, demand for more reliable regenerative solutions continues to rise. Furthermore, with a growing geriatric population, many patients present compromised healing potential, making biologically passive grafts insufficient for predictable outcomes.

As a result, research is increasingly moving toward advanced, multifunctional strategies that better replicate natural bone structure and function. These approaches include tissue-engineered scaffolds, stem cell–based treatments, growth factor delivery systems, smart biomaterials, and patient-specific 3D-printed constructs. The goal of these next-generation methods is to integrate biological activity, mechanical integrity, and controlled degradation— properties that conventional grafts cannot achieve together. In conclusion, although traditional bone grafting has long been a cornerstone of orthopedic repair, its limitations in safety, biological effectiveness, and scalability emphasize the necessity for innovative regenerative solutions. Emerging biomaterial-based technologies offer strong potential for more reliable, functional, and long-lasting bone regeneration.

Unaddressed medical demand highlighting the need for Innovative Solutions Successful bone regeneration depends on scaffolds degrading at a rate that closely matches the natural bone healing process, ensuring both mechanical stability and gradual tissue replacement. Bone healing progresses through hematoma formation, soft callus development, hard callus formation, and long-term remodeling. Therefore, an ideal scaffold should maintain structural integrity for at least 8–12 weeks, degrade by approximately 50–70% within 2–4 months, and achieve near-complete resorption within 6–18 months. This balance allows new bone tissue to progressively replace the scaffold while preserving load-bearing support during healing [27].

Current biomaterials vary significantly in their degradation profiles and clinical performance. Hydroxyapatite (HA) and polycaprolactone (PCL) degrade very slowly, often remaining for years and potentially causing stress shielding, chronic inflammation, fibrous encapsulation, and incomplete remodeling. In contrast, collagen, alginate, and some bioglasses degrade too rapidly, resulting in premature mechanical failure, implant instability, and delayed or nonunion healing. Materials such as β-tricalcium phosphate (β-TCP), chitosan, and tunable PLGA systems demonstrate more favorable degradation behavior, although PLGA may produce acidic byproducts that trigger inflammation [28].

In addition to degradation mismatches, major unmet clinical challenges include poor vascularization in large bone defects, insufficient mechanical strength for weight-bearing applications, limited osteoinductive signaling, and inefficient growth factor delivery caused by burst-release kinetics. High manufacturing costs and regulatory barriers further limit clinical translation. Consequently, next-generation strategies focus on smart composite biomaterials, ion-releasing nanoparticles, 3D-printed patient-specific scaffolds, stem cell integration, and controlled drug delivery systems designed to improve angiogenesis, osteogenesis, mechanical performance, and long-term bone regeneration outcomes [29,30].

Enhancements in bone scaffolds

The intersection of biotechnology and bioprinting represents a transformative frontier in regenerative medicine, where custom-designed scaffolds are driving breakthroughs in bone and cartilage tissue restoration. While significant progress has been made, several challenges remain that can be addressed through

the integration of nanotechnology, bioengineering, smart technology, and bioanalogous strategies.

A key limitation of some scaffolds is their lack of load-bearing capacity, particularly in large bone defects. Additionally, brittle ceramic-based scaffolds often fail under mechanical stress. These issues can be mitigated by:

- Integrating hybrid nanocomposites, such as graphene oxide, hydroxyapatite, and bioglass, to reinforce scaffolds.
- Fabricating multi-layered scaffolds with rigid cores and porous, bioactive outer layers.
- Utilizing bioinspired hierarchical designs that mimic trabecular bone microarchitecture, often employing 3D-printed lattice structures to enhance strength and flexibility.
- Incorporating smart self-healing materials that respond to microfractures, thereby prolonging scaffold lifespan.

Furthermore, the creation of enzyme-sensitive crosslinking systems enables hydrogels to degrade in the presence of bone-specific enzymes. This enhances synchronization with the natural process of bone remodeling, ensuring seamless integration of materials and improved tissue regeneration. Computational modeling can be used to tailor degradation rates based on bone healing stages, and incorporating pH-responsive polymers to release bioactive components in response to local inflammatory environments promises to improve scaffold biodegradation and longevity.

Current scaffolds often lack strong osteoconductive signals, necessitating high doses of BMP-2 and VEGF, increasing risks of ectopic bone formation. This limitation can be adressed by:

- Incorporating bioactive peptides.
- Utilizing ion-releasing nanoparticles, such as magnesium and strontium ions, to enhance bone mineralization and angiogenesis.
- Functionalizing scaffolds with extracellular matrix-like proteins (e.g., collagen) to enhance cell adhesion and differentiation.

Traditional growth factor delivery methods often suffer from burst release kinetics, leading to rapid degradation and limited bioactivity over time. This can be improved by encapsulating nanocarrier-based growth factors, such as BMP-2, VEGF, and TGF-β3, in PLGA nanoparticles to achieve sustained, controlled release, ensuring localized, time-dependent osteogenic stimulation. Layer-by-layer drug deposition via electrostatic self-assembly enables sequential growth factor release, mimicking natural bone healing cascades.

In recent advancements, many promising scaffold designs fail due to high production costs and regulatory challenges are faced. This can be standardized with scaffold fabrication for mass production that ensures scalability and patient-specific designs. Development of cost-effective natural polymer scaffolds are the lower cost alternatives. Conducting preclinical trials in large animals (e.g. such as sheep, pigs) to validate scaffold safety and effectiveness before human applications. Finally, the issue of synthetic biomaterials triggering immune rejection, which can lead to fibrosis or implant failure can be mitigated by functionalizing scaffolds with immunomodulatory peptides such as IL-10 and TGF-β mimetics. These peptides suppress pro-inflammatory cytokines and enhance tissue remodeling. Self-assembling ECM-inspired peptides can also mimic the biochemical cues of native bone, enhancing integration with host tissues.

Controlled drug and growth factor delivery

Growth factor delivery in bone tissue engineering faces major challenges due to the short half-life and instability of biomolecules such as BMP-2, VEGF, and TGF-β3. Conventional delivery methods often cause rapid degradation and uncontrolled burst release, reducing therapeutic effectiveness and increasing side effects. To overcome these limitations, nanoparticle-based delivery systems such as PLGA and chitosan nanoparticles are being developed to protect growth factors and provide sustained, localized release. Layer-by-layer drug deposition techniques further enable sequential and controlled release of osteogenic and angiogenic factors, mimicking natural bone healing while minimizing inflammation. In addition, stimuli-responsive hydrogels, including pH-sensitive and enzyme-triggered systems, allow on-demand drug release and scaffold degradation synchronized with bone remodeling. Together, these advanced strategies improve growth factor stability, bioavailability, and overall bone regeneration outcomes [34-40].

Translational challenges and clinical applications

The clinical translation of biomaterial scaffolds and 3D bioprinting technologies faces significant challenges related to scalability, regulatory approval, preclinical validation, and cost-effective manufacturing [41]. Traditional scaffold fabrication methods often lack reproducibility and large-scale production capability, emphasizing the need for automated bioprinting and AI-driven quality control systems [42]. In addition, regulatory agencies such as the FDA and EMA require extensive

evaluation of scaffold biocompatibility, degradation behavior, and mechanical stability before clinical approval [43].

Preclinical validation increasingly relies on large animal models, such as sheep and pigs, because they better replicate human bone healing compared to rodents [44-45]. Recent clinical trials involving bioprinted scaffolds, peptide hydrogels, and nanocomposite implants have demonstrated promising outcomes in bone regeneration [46-47]. However, achieving long-term integration, immune compatibility, and consistent therapeutic efficacy remains challenging.

Future personalized bone regeneration strategies focus on AI-assisted bioprinting, patient-derived mesenchymal stem cells, and CT/MRI-guided customized scaffold fabrication [48-49]. These approaches improve precision, reduce immune rejection, and optimize scaffold architecture and mechanical performance [50]. Overall, advancements in biomaterials, AI-driven manufacturing, and regulatory standardization are expected to accelerate the development of safe, scalable, and patient-specific regenerative therapies for bone and cartilage repair [50-51].

Emerging Trends and Future research perspective

Future directions in bone tissue engineering focus on overcoming major barriers to clinical translation through advanced biomaterials, artificial intelligence (AI), and innovative biofabrication technologies. One major priority is improving vascularization in large bone defects using pre-vascularized scaffolds, endothelial progenitor cells, controlled VEGF delivery, and microfluidic vascular networks. Future scaffolds are also expected to provide precise spatiotemporal control of biological signaling by enabling the controlled release of multiple growth factors that mimic natural bone healing processes.

Another promising direction involves immunomodulatory scaffolds that actively regulate immune responses and promote regenerative macrophage activity rather than simply avoiding rejection. In addition, large-scale clinical adoption will require standardized and AI-assisted manufacturing systems capable of producing reproducible, high-quality scaffolds.

Future research is increasingly integrating advanced scaffolds with biologically based therapies such as stem cells, gene delivery, and exosome treatments to enhance regeneration of critical-sized bone defects. AI-driven computational modeling is also enabling patient-specific scaffold designs optimized for porosity, degradation behavior, and bioactive molecule release. Furthermore, multifunctional biomimetic scaffolds incorporating nanocomposites, bioactive peptides, and stimuli-responsive hydrogels are being developed to improve tissue integration and long-term stability. Smart nanocarrier-based drug delivery systems for sustained and localized release of growth factors such as BMP-2, VEGF, and TGF-β3 are expected to further enhance bone regeneration while reducing adverse effects [52,53].

Economic aspects of Bone Tissue Engineering

Bone tissue engineering (BTE) has emerged as a promising strategy for repairing bone defects caused by trauma, disease, infection, and tumor resection. Although traditional grafting methods such as autografts and allografts are widely used, they are associated with limitations including donor site morbidity, infection risk, immune reactions, and limited availability. As BTE approaches clinical translation, economic feasibility has become a major consideration.

The global orthopaedic biomaterials market is valued at approximately USD 17–20 billion, while the bone graft and substitute sector accounts for nearly USD 3–4 billion annually. High rates of fracture non-union and revision surgeries create substantial healthcare costs, highlighting the potential economic benefits of advanced regenerative therapies. However, BTE technologies remain expensive due to biomaterial fabrication, stem cell processing, growth factor production, GMP-compliant manufacturing, and regulatory requirements. Scaffold costs vary depending on materials and fabrication methods, while cell-based therapies and recombinant growth factors such as BMP-2 significantly increase treatment expenses.

Despite high initial costs, BTE may provide long-term economic advantages by reducing complications, revision surgeries, hospitalization time, and productivity loss. Technologies that lower complication rates by 20–30% are considered potentially cost-effective within value-based healthcare systems. However, reimbursement limitations, regulatory complexity, and surgeon adoption remain major barriers, particularly for cell-based therapies. Future economic trends suggest that cell-free smart biomaterials, AI-assisted manufacturing, automation, and 3D-printed patient-specific implants will improve scalability and reduce production costs. As technologies mature and regulatory pathways become clearer, BTE is expected to achieve broader clinical adoption and market growth [54, 55].

Summary

The combination of smart biomaterials, artificial intelligence (AI), and advanced biofabrication technologies is significantly advancing bone and cartilage regeneration. Innovations involving nanotechnology, peptide-based hydrogels, and 3D bioprinting have enabled the development of highly functional scaffolds with enhanced biocompatibility, mechanical strength, and bioactivity. Despite these advancements,

important challenges such as immune reactions, inadequate mechanical stability, and uncontrolled degradation rates continue to limit clinical translation. Future progress will depend on the development of multifunctional and customizable scaffold systems supported by AI-based optimization to improve therapeutic performance, scalability, and long-term regenerative outcomes.

References

[1] Sun, W., Starly, B., Daly, A. C., Burdick, J. A., Groll, J., Skeldon, G., Shu, W., Sakai, Y., Shinohara, M., Nishikawa, M., Jang, J., Cho, D., Nie, M., Takeuchi, S., Ostrovidov, S., Khademhosseini, A., Kamm, R. D., Mironov, V., Moroni, L., & Ozbolat, I. T. (2020). The bioprinting roadmap. *Biofabrication*, *12*(2), 022002. https://doi.org/10.1088/1758-5090/ab5158

[2] Xiong, Z., Wu, J., Liu, Z., & Jing, W. (2019). Moderate osteoporosis itself is beneficial for bones. *Medical Hypotheses*, *134*, 109427. https://doi.org/10.1016/j.mehy.2019.109427

[3] Dimitriou, R., Jones, E., McGonagle, D., & Giannoudis, P. V. (2011). Bone regeneration: current concepts and future directions. *BMC Medicine*, *9*(1). https://doi.org/10.1186/1741-7015-9-66

[4] Ho-Shui-Ling, A., Bolander, J., Rustom, L. E., Johnson, A. W., Luyten, F. P., & Picart, C. (2018). Bone regeneration strategies: Engineered scaffolds, bioactive molecules and stem cells current stage and future perspectives. *Biomaterials*, *180*, 143–162. https://doi.org/10.1016/j.biomaterials.2018.07.017

[5] Winkler, T., Sass, F. A., Duda, G. N., & Schmidt-Bleek, K. (2018). A review of biomaterials in bone defect healing, remaining shortcomings and future opportunities for bone tissue engineering. *Bone and Joint Research*, *7*(3), 232–243. https://doi.org/10.1302/2046-3758.73.bjr-2017-0270.r1

[6] Tang, D., Tare, R. S., Yang, L., Williams, D. F., Ou, K., & Oreffo, R. O. (2016). Biofabrication of bone tissue: approaches, challenges and translation for bone regeneration. *Biomaterials*, *83*, 363–382. https://doi.org/10.1016/j.biomaterials.2016.01.024

[7] Feng, P., He, J., Peng, S., Gao, C., Zhao, Z., Xiong, S., & Shuai, C. (2019). Characterizations and interfacial reinforcement mechanisms of multicomponent biopolymer based scaffold. *Materials Science and Engineering C*, *100*, 809–825. https://doi.org/10.1016/j.msec.2019.03.030

[8] Wang, W., & Yeung, K. W. (2017). Bone grafts and biomaterials substitutes for bone defect repair: A review. *Bioactive Materials*, *2*(4), 224–247. https://doi.org/10.1016/j.bioactmat.2017.05.007

[9] Bullock, G., Atkinson, J., Gentile, P., Hatton, P., & Miller, C. (2021). Osteogenic peptides and attachment methods determine tissue regeneration in modified bone graft substitutes. *Journal of Functional Biomaterials*, *12*(2), 22. https://doi.org/10.3390/jfb12020022

[10] Ai, C., Lee, Y. H. D., Tan, X. H., Tan, S. H. S., Hui, J. H. P., & Goh, J. C. (2021). Osteochondral tissue engineering: Perspectives for clinical application and preclinical development. *Journal of Orthopaedic Translation*, *30*, 93–102. https://doi.org/10.1016/j.jot.2021.07.008

[11] Kapat, K., Kumbhakarn, S., Sable, R., Gondane, P., Takle, S., & Maity, P. (2024). Peptide-Based biomaterials for bone and cartilage regeneration. *Biomedicines*, *12*(2), 313. https://doi.org/10.3390/biomedicines12020313

[12] Zhou, A., Chen, S., He, B., Zhao, W., Chen, X., & Jiang, D. (2016). Controlled release of TGF-beta 1 from RADA self-assembling peptide hydrogel scaffolds. *Drug Design Development and Therapy*, *Volume 10*, 3043–3051. https://doi.org/10.2147/dddt.s109545

[13] Jia, J., Siheng, W., Fang, C., Chengchong, A., & Shiyi, C. (2016). The study on vascularisation and osteogenesis of BMP/VEGF co-modified tissue engineering bone in vivo. *RSC Advances*, *6*(48), 41800–41808. https://doi.org/10.1039/c6ra03111k

[14] Zhang, Q., Liu, Y., Li, J., Wang, J., & Liu, C. (2022). Recapitulation of growth factor-enriched microenvironment via BMP receptor activating hydrogel. *Bioactive Materials*, *20*, 638–650. https://doi.org/10.1016/j.bioactmat.2022.06.012

[15] Van Der Rest, M., & Garrone, R. (1991). Collagen family of proteins. *The FASEB Journal*, *5*(13), 2814–2823. https://doi.org/10.1096/fasebj.5.13.1916105

[16] Zhang, T., Li, J., Wang, Y., Han, W., Wei, Y., Hu, Y., Liang, Z., Lian, X., & Huang, D. (2023). Hydroxyapatite/Polyurethane scaffolds for bone tissue engineering. *Tissue Engineering Part B Reviews*, *30*(1), 60–73. https://doi.org/10.1089/ten.teb.2023.0073

[17] Bose, S., Vahabzadeh, S., & Bandyopadhyay, A. (2013). Bone tissue engineering using 3D printing. *Materials Today*, *16*(12), 496–504. https://doi.org/10.1016/j.mattod.2013.11.017

[18] Govindarajan, D., Saravanan, S., Sudhakar, S., & Vimalraj, S. (2023). Graphene: a multifaceted Carbon-Based material for bone tissue engineering applications. *ACS Omega*, *9*(1), 67–80. https://doi.org/10.1021/acsomega.3c07062

[19] N, D. a. P., H, D. a. A., Pena, P., & S, D. A. (2022). Bioactive glasses and Glass-Ceramics. In *Wiley eBooks*. https://doi.org/10.1002/9781119724193

[20] Kim, K., Yeatts, A., Dean, D., & Fisher, J. P. (2010). Stereolithographic bone scaffold design parameters: osteogenic differentiation and signal expression. *Tissue Engineering Part B Reviews*, *16*(5), 523–539. https://doi.org/10.1089/ten.teb.2010.0171

[21] Murphy, S. V., & Atala, A. (2014). 3D bioprinting of tissues and organs. *Nature Biotechnology*, *32*(8), 773–785. https://doi.org/10.1038/nbt.2958

[22] Sultana, N., Cole, A., & Strachan, F. (2024). Biocomposite scaffolds for tissue Engineering: materials, fabrication techniques and future directions. *Materials*, *17*(22), 5577. https://doi.org/10.3390/ma17225577

[23] Tupe, A., Patole, V., Ingavle, G., Kavitkar, G., Tiwari, R. M., Kapare, H., Baheti, R., & Jadhav, P. (2024). Recent advances in Biomaterial-Based scaffolds for guided bone tissue Engineering: challenges and future directions. *Polymers for Advanced Technologies*, *35*(11). https://doi.org/10.1002/pat.6619

[24] Brachet, A., Bełżek, A., Furtak, D., Geworgjan, Z., Tulej, D., Kulczycka, K., Karpiński, R., Maciejewski, M., & Baj, J. (2023). Application of 3D printing in bone grafts. *Cells*, *12*(6), 859. https://doi.org/10.3390/cells12060859

[25] Vinogradova, T. I., Serdobintsev, M. S., Korzhikova-Vlakh, E. G., Korzhikov-Vlakh, V. A., Kaftyrev, A. S., Blum, N. M., Semenova, N. Y., Esmedlyaeva, D. S., Dyakova, M. E., Nashchekina, Y. A., Dogonadze, M. Z., Zabolotnykh, N. V., & Yablonsky, P. K. (2023). Comparison of Autografts and Biodegradable 3D-Printed Composite Scaffolds with Osteoconductive Properties for Tissue Regeneration in Bone Tuberculosis. *Biomedicines*, *11*(8), 2229. https://doi.org/10.3390/biomedicines11082229

[26] Steijvers, E., Ghei, A., & Xia, Z. (2022). Manufacturing artificial bone allografts: a perspective. *PubMed*, *3*(1), 65–80. https://doi.org/10.12336/biomatertransl.2022.01.007

[27] Xing, F., Xiang, Z., Rommens, P. M., & Ritz, U. (2020). 3D bioprinting for vascularized Tissue-Engineered bone fabrication. *Materials*, *13*(10), 2278. https://doi.org/10.3390/ma13102278

[28] Sarker, M. D., Naghieh, S., Sharma, N. K., Ning, L., & Chen, X. (2019). Bioprinting of vascularized tissue scaffolds: influence of biopolymer, cells, growth factors, and gene delivery. *Journal of Healthcare Engineering*, *2019*, 1–20. https://doi.org/10.1155/2019/9156921

[29] Kačarević, Ž. P., Rider, P. M., Alkildani, S., Retnasingh, S., Smeets, R., Jung, O., Ivanišević, Z., & Barbeck, M. (2018). An Introduction to 3D bioprinting: possibilities, challenges and future aspects. *Materials*, *11*(11), 2199. https://doi.org/10.3390/ma11112199

[30] Jammalamadaka, U., & Tappa, K. (2018). Recent advances in biomaterials for 3D printing and tissue engineering. *Journal of Functional Biomaterials*, *9*(1), 22. https://doi.org/10.3390/jfb9010022

[31] Zhang, X., Zhang, X., Li, Y., & Zhang, Y. (2023). Applications of Light-Based 3D Bioprinting and Photoactive Biomaterials for Tissue Engineering. *Materials (Basel, Switzerland)*, *16*(23), 7461. https://doi.org/10.3390/ma16237461

[32] Willson, K., Ke, D., Kengla, C., Atala, A., & Murphy, S. V. (2020). Extrusion-Based Bioprinting: Current standards and Relevancy for Human-Sized Tissue Fabrication. *Methods in Molecular Biology*, 65–92. https://doi.org/10.1007/978-1-0716-0520-2_5

[33] Kumar, H., & Kim, K. (2020). Stereolithography 3D bioprinting. *Methods in Molecular Biology*, 93–108. https://doi.org/10.1007/978-1-0716-0520-2_6

[34] Freeman, F. E., Pitacco, P., Van Dommelen, L. H. A., Nulty, J., Browe, D. C., Shin, J., Alsberg, E., & Kelly, D. J. (2020). 3D bioprinting spatiotemporally defined patterns of growth factors to tightly control tissue regeneration. *Science Advances*, *6*(33). https://doi.org/10.1126/sciadv.abb5093

[35] Jain, K., Shukla, R., Yadav, A., Ujjwal, R. R., & Flora, S. J. S. (2021). 3D printing in development of nanomedicines. *Nanomaterials*, *11*(https://doi.org/10.3390/nano11020420

[36] Choe, G., Lee, M., Oh, S., Seok, J. M., Kim, J., Im, S., Park, S. A., & Lee, J. Y. (2022). Three-dimensional bioprinting of mesenchymal stem cells using an osteoinductive bioink containing alginate and BMP-2-loaded PLGA nanoparticles for bone tissue engineering. *Biomaterials Advances*, *136*, 212789. https://doi.org/10.1016/j.bioadv.2022.212789

[37] Mallakpour, S., Sirous, F., & Hussain, C. M. (2021). Current achievements in 3D bioprinting technology of chitosan and its hybrids. *New Journal of Chemistry*, *45*(24), 10565–10576. https://doi.org/10.1039/d1nj01497h

[38] Patel, S. K., Khoder, M., Peak, M., & Alhnan, M. A. (2021). Controlling drug release with additive manufacturing-based solutions. *Advanced Drug Delivery Reviews*, *174*, 369–386. https://doi.org/10.1016/j.addr.2021.04.020

[39] Dutta, S., & Cohn, D. (2017). Temperature

and pH responsive 3D printed scaffolds. *Journal of Materials Chemistry B*, *5*(48), 9514–9521. https://doi.org/10.1039/c7tb02368e

[40] Shen, J., Zhang, S., Fang, X., & Salmon, S. (2022). Advances in 3D gel printing for enzyme immobilization. *Gels*, *8*(8), 460. https://doi.org/10.3390/gels8080460

[41] Vijayavenkataraman, S. (2023). 3D bioprinting: challenges in commercialization and clinical translation. *Journal of 3D Printing in Medicine*, *7*(2). https://doi.org/10.2217/3dp-2022-0026

[42] Chen, L., Guttieres, D., Koenigsberg, A., Barone, P. W., Sinskey, A. J., & Springs, S. L. (2021). Large-scale cultured meat production: Trends, challenges and promising biomanufacturing technologies. *Biomaterials*, *280*, 121274. https://doi.org/10.1016/j.biomaterials.2021.121274

[43] Mladenovska, T., Choong, P. F., Wallace, G. G., & O'Connell, C. D. (2023). The regulatory challenge of 3D bioprinting. *Regenerative Medicine*, *18*(8), 659–674. https://doi.org/10.2217/rme-2022-0194

[44] Hatt, L. P., Thompson, K., Helms, J. A., Stoddart, M. J., & Armiento, A. R. (2022). Clinically relevant preclinical animal models for testing novel cranio-maxillofacial bone 3D-printed biomaterials. *Clinical and Translational Medicine*, *12*(2). https://doi.org/10.1002/ctm2.690

[45] Xin, H., Ferguson, B. M., Wan, B., Maruf, D. S. a. A., Lewin, W. T., Cheng, K., Kruse, H. V., Leinkram, D., Parthasarathi, K., Wise, I. K., Froggatt, C., Crook, J. M., McKenzie, D. R., Li, Q., & Clark, J. R. (2024). A preclinical trial protocol using an Ovine model to assess scaffold implant biomaterials for repair of Critical-Sized mandibular defects. *ACS Biomaterials Science & Engineering*, *10*(5), 2863–2879. https://doi.org/10.1021/acsbiomaterials.4c00262

[46] Yazdanpanah, Z., Johnston, J. D., Cooper, D. M. L., & Chen, X. (2022). 3D Bioprinted scaffolds for bone tissue Engineering: State-Of-The-Art and Emerging Technologies. *Frontiers in Bioengineering and Biotechnology*, *10*. https://doi.org/10.3389/fbioe.2022.824156

[47] Pavek, A., Nartker, C., Saleh, M., Kirkham, M., Pour, S. K., Aghazadeh-Habashi, A., & Barrott, J. J. (2021). Tissue engineering through 3D bioprinting to recreate and study bone disease. *Biomedicines*, *9*(5), 551. https://doi.org/10.3390/biomedicines9050551

[48] Nosrati, H., & Nosrati, M. (2023). Artificial intelligence in Regenerative Medicine: Applications and implications. *Biomimetics*, *8*(5), 442. https://doi.org/10.3390/biomimetics8050442

[49] Sahai, N., & Gogoi, M. (2020). 3D tissue scaffold library development form medical images for bioprinting application. *Materials Today Proceedings*, *26*, 399–404. https://doi.org/10.1016/j.matpr.2019.12.063

[50] Bhardwaj, N., Sood, M., & Gill, S. S. (2024). 3D-Bioprinting and AI-empowered Anatomical Structure Designing: a review. *Current Medical Imaging Formerly Current Medical Imaging Reviews*, *20*. https://doi.org/10.2174/0115734056259274231019061329

[51] Kilian, D., Sembdner, P., Bretschneider, H., Ahlfeld, T., Mika, L., Lützner, J., Holtzhausen, S., Lode, A., Stelzer, R., & Gelinsky, M. (2021). 3D printing of patient-specific implants for osteochondral defects: workflow for an MRI-guided zonal design. *Bio-Design and Manufacturing*, *4*(4), 818–832. https://doi.org/10.1007/s42242-021-00153-1

[52] Van Der Stok, J., Van Lieshout, E. M., El-Massoudi, Y., Van Kralingen, G. H., & Patka, P. (2010). Bone substitutes in the Netherlands – A systematic literature review. *Acta Biomaterialia*, *7*(2), 739–750. https://doi.org/10.1016/j.actbio.2010.07.035

[53] Choe, G., Lee, M., Oh, S., Seok, J. M., Kim, J., Im, S., Park, S. A., & Lee, J. Y. (2022). Three-dimensional bioprinting of mesenchymal stem cells using an osteoinductive bioink containing alginate and BMP-2-loaded PLGA nanoparticles for bone tissue engineering. *Biomaterials Advances*, *136*, 212789. https://doi.org/10.1016/j.bioadv.2022.212789

[54] Liu, S., & Jin, P. (2025). Advances and Challenges in 3D Bioprinted Cancer Models: Opportunities for Personalized Medicine and Tissue Engineering. *Polymers*, *17*(7), 948. https://doi.org/10.3390/polym17070948

[55] Ramadan, Q., & Zourob, M. (2021). 3D bioprinting at the frontier of regenerative medicine, pharmaceutical, and food industries. *Frontiers in Medical Technology*, *2*. https://doi.org/10.3389/fmedt.2020.607648.